MGUS Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about MGUS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment

Multiple MyelomaMGUSAL Amyloidosis+1 more
Fondazione IRCCS Policlinico San Matteo di Pavia100 enrolled1 locationNCT07448779
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled13 locationsNCT06140524
Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Multiple MyelomaSmoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)+2 more
Wake Forest University Health Sciences1,665 enrolled1 locationNCT06644625
Recruiting

European Myeloma Network (EMN) Sample Project

Multiple MyelomaSmoldering Multiple MyelomaPlasma Cell Leukemia+2 more
European Myeloma Network B.V.6,000 enrolled41 locationsNCT06237803
Recruiting

Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy

Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance (MGUS)M-Protein+1 more
Zhujiang Hospital2,990 enrolled1 locationNCT06690593
Recruiting

Intestinal Flora and Immunity in Monoclonal Gammopathy Patients

Multiple MyelomaInfectionsMGUS+2 more
Zhujiang Hospital300 enrolled1 locationNCT06539832
Recruiting

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Multiple MyelomaAmyloidosisSmoldering Multiple Myeloma+9 more
Peking University First Hospital2,000 enrolled1 locationNCT05283993